guidanc lower due
report top/bottomlin beat driven demand lower
guidanc account impact well acceler
convers ultomiri key posit due price headwind
latter like driven need reduc healthcar burden soliri
ultomiri compani note potenti lag month
current enrol trial signific impact fulli enrol trial
model updat result guidanc ahead august ipr
decis key overhang expect stock trade band
reiter buy rate new pt
takeaway call beat consensu
top vs con bottom-lin vs driven
increas demand guidanc lower top-line bottom-line well
expens top-line guidanc mid-point
previou guidanc non-gaap sg versu
non-gaap versu prev non-
gaap ep mid-point prev guidanc
top-line guidanc lower account potenti impact includ
slow new patient start acceler convers ultomiri
posit price headwind convers us germani japan
potenti lower complianc signific impact fulli enrol
clinic trial lag least month current enrol trial anticip
model updat updat model result updat
guidanc chang model includ convert major
high dose pnh patient ultomiri account price headwind
combin neurolog build easili account patient metric
provid neurolog franchis updat mg nmosd monthli
build better align current launch trajectori updat
revenu versu
previous new pt
addit color talk manag around impact
remind major patient commerci insur
medicar part manag note impact high unemploy
rate take time rippl economi busi impact patient
switch medicaid like seen compani anticip re-
tr target
open medic access juli expect time re-open return normalci
fcrn studi delay due could still competit
compani develop iv subq version fcrn molecul howev due
associ concern pivot trial waiha iv version hv trial subq
version paus expect initi view fcrn
competit landscap multipl player potenti ahead pleas see fcrn deep
dive management believ fcrn posit destabil steroids/immunosuppress cycl
therapi also believ fcrn competit landscap big term market potenti
product differenti could come rout administr igg reduct shape reduct
safeti management also maintain despit later game gmg footprint
gmg like give competit advantag current model valu fcrn
catalyst subq ultomiri bridg studi data phase data danicopan
buy ipr decis august competitor data gmg
argenx argx buy imvt buy buy pdufa date
ultomiri formul launch pivot data nave patient
page
figur million dollar except per share data
strh research compani report updat
page
incom statement market productsproduct revenu sale pediatr unadjustedultomiri non-refractori al product oper oper itemsinvest interest incom currenc gain expens incom exc spec tax incom non-gaap cash tax excl stock ep ex-opt tax net incom non-gaap ep incl share share share dilut use non-gaap inc
alexion pharmaceut inc biopharmaceut compani focus serv patient
devast ultra-rar disord develop commerci life-
transform therapeut product compani product includ ultomiri soliri strensiq
kanuma compani found joseph madri david keiser stephen squinto
leonard bell januari headquart boston
buy-rat share next month think
investor clariti us pnh patent see risk reward buy
karnauska ipr favor current level recommend own alexion
ipr outcom august believ investor expect win alexion
lose soliri pnh patent win see upsid uncertainti remov
lose could even upsid pt
view current valu stock reflect invalid alexion us pnh patent
price pressur soliri keep market share approv indic
credit pipelin believ unrealist given convers ultomiri go ahead
expect model give signific share biosimilar us eu
also believ compani could beat consensu estim see qualiti
compani execut repeatedli beat expect mg growth ultomiri
see data apelli nr pnh argenx argx buy momenta
buy karnauska immunov imvt buy karnauska mg apelli studi head
head soliri believ soliri patient extravascular hemolysi
smaller investor believ rout administr challeng
mani patient ultomiri dose everi two month also believ current level assum
competit model
acknowledg stock may achiev upsid tp ahead ipr
uncertainti consensu estim beyond appear erod alexion
busi much may need come
valuat risk
pt deriv use dcf use discount factor believ appropri
larg cap biotech lower risk profil competit risk versu peer assum
termin valu reflect alexion creat valu cash gener assum alexion lose ipr
august soliris/ultomiri make follow assumpt pnh share ultomiri
competit biosimilar ahu share ultomiri competit
biosimilar mg ultomiri competit biosimilar peak
treat us neurolog patient despit popul nmo ultomiri
competit biosimilar price model price cut soliri ultomiri
competit give zero valu pipelin
risk rate price target includ price share erod greater faster expect
greater competit clinic trial failur pipelin
compani mention note
robyn karnauska herebi certifi view express research report accur reflect
person view subject compani secur also certifi
page
receiv direct indirect compens exchang express specif
recommend report
suntrust robinson humphrey inc make market follow compani alxn-u amgn-u
argx-u imvt-u mnta-u
suntrust robinson humphrey inc affili manag co-manag secur offer
follow compani within last month imvt-u
follow compani client suntrust robinson humphrey inc invest bank servic
within last month imvt-u
suntrust robinson humphrey inc affili receiv compens invest bank
servic within last month imvt-u
analyst compens base upon stock price perform qualiti analysi commun skill
overal revenu profit firm includ invest bank revenu
matter polici practic firm prohibit offer favor research specif
research rate specif target price consider induc receipt busi
compens addit associ person prepar research report prohibit own
secur subject compani
rate price target histori inc alxn-u
rate price target histori amgen inc amgn-u
creat bluematrix
creat bluematrix
page
rate price target histori argenx se adr argx-u
rate price target histori immunov inc imvt-u
creat bluematrix
rate price target histori inc mnta-u
creat bluematrix
creat bluematrix
strh rate system equiti secur
dissemin research
suntrust robinson humphrey strh seek make reason effort provid research report
simultan elig client report avail publish restrict access area
websit elig client request password institut investor corpor
member press may also receiv research via third parti vendor includ thomson reuter
bloomberg factset capit iq addit distribut may done sale personnel via
email fax electron mean regular mail
access third parti vendor research websit http //suntrustlibrari bluematrix com/client/
pleas email research depart
contact strh sale repres
strh rate equiti secur
page
rate rel broader market gener next month unless
buy stock total return expect outperform relev benchmark
hold stock total return expect perform line relev benchmark
next month unless otherwis indic
sell stock total return expect under-perform relev benchmark
next month unless otherwis indic
rate nr strh invest rate opinion stock
coverag suspend cs indic strh rate and/or target price temporarili
suspend due applic regul and/or strh manag discret previous publish
rate target price reli upon
strh analyst price target stock cover unless otherwis indic price
target repres analyst expect stock trade next month unless
otherwis indic analyst believ insuffici valuat driver and/or invest
catalyst deriv posit neg invest view may elect approv strh
research manag assign target price likewis certain stock trade may
exhibit volatil wherebi assign price target would unhelp make invest decis
research manag approv analyst may refrain assign target sub-
legend rate price target histori chart
suntrust robinson humphrey rate distribut
